EU Officials Note Similarities In Post-Approval Changes For Biosimilars, Reference Drugs
Executive Summary
EU pharmaceutical and industry officials note some common trends and similarities in post-approval changes for biosimilars and reference products. One vexing problem in instituting post-approval changes is whether to use the reference drug or the approved biosimilar and regulatory guidance in this area is lacking.